Global Liver Cirrhosis Therapeutics Market 2016-2020

Market outlook of liver cirrhosis therapeutics

According to the liver cirrhosis therapeutics industry analysis, Technavio’s research analyst predicts the global liver cirrhosis therapeutics market to grow moderately at a CAGR of over 4% during the forecast period. Liver diseases such as cirrhosis, hepatitis, liver cancer, and nonalcoholic fatty liver disease have become prevalent among the population worldwide, hence the consumption of medications that manage liver diseases is likely to increase, which in turn will drive the growth of the liver cirrhosis therapeutics market.

Increased public awareness of liver cirrhosis is also leading to the growth of the liver cirrhosis therapeutics market value. The early detection of infections is important in reducing disease progression. For instance, the early screening and diagnosis of hepatitis C and B infections can prevent or reduce the extent of liver damage. Many government and nongovernmental organizations have been organizing awareness campaigns, seminars, summits, and fundraising events to educate people about the diseases and therapeutic measures available. These awareness programs are leading to more people opting for therapeutic drugs for treatment, increasing drug consumption and their revenues.

Segmentation by type of the liver cirrhosis therapeutics market

• Alcoholic cirrhosis
• Postnecrotic cirrhosis
• Biliary cirrhosis
• Cardiac cirrhosis

Alcoholic cirrhosis is the most common type of liver cirrhosis and occupied the largest share in the liver cirrhosis therapeutics market with a market share of about 60% during 2015. Factors such as increased prevalence of liver diseases and change in the lifestyle patterns are expected to propel the market growth. Lifestyle factors such as obesity, smoking, intake of alcohol and dietary sodium have been found to increase the risk of liver cirrhosis. According to a 2011 study, nearly half of all the liver disease cases occur due to alcohol and tobacco-related health hazards.

Geographical segmentation and analysis of the liver cirrhosis therapeutics market

• Americas
• APAC
• Europe
   

In this market research report, Technavio’s analysts have envisaged the Americas to be the largest market for liver cirrhosis therapeutics during the forecast period. High incidences of liver diseases such as liver cirrhosis in regions like the US and Canada and hepatitis in Latin America is a significant factor, which is expected to result in the region’s market share of about 49% by 2020.

Competitive landscape and key vendors

The existence of high unmet medical needs, such as the adverse effects of drugs, presents a vast opportunity for vendors to develop molecules that have better efficacy and safety profiles for the treatment of liver cirrhosis. This will create a strong competition among small and large players in the liver cirrhosis therapeutics market who will compete on the basis of price, quality, and innovation.

The leading vendors in the market are -

• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson
• Merck
• Roche

Other prominent vendors in the market include Bristol-Myers Squibb, Conatus Pharmaceuticals, Gwo Xi Stem Cell Applied Technology, Instituto Grifols, Intercept Pharmaceuticals, NGM Biopharmaceuticals, Norgine, Pharmicell, Salix Pharmaceuticals, and Stempeutics Research.

Key questions answered in the report include

• What will the liver cirrhosis therapeutics market size and the growth rate be in 2020?
• What are the key factors driving the global liver cirrhosis therapeutics market?
• What are the key liver cirrhosis therapeutics market trends impacting the growth of the market?
• What are the challenges to market growth?
• Who are the key vendors in the global liver cirrhosis therapeutics market?
• What are the market opportunities and threats faced by the vendors in the global liver cirrhosis therapeutics market?
• Trending factors influencing the market shares of the Americas, APAC, and Europe.
• What are the key outcomes of the five forces analysis of the global liver cirrhosis therapeutics market?

Technavio also offers customization on reports based on specific client requirement.

Related reports:

• Global Liver Diseases Therapeutics Market 2015-2019
• Global Hepatitis Drugs Market 2015-2019
• Cystic Fibrosis Market in Europe 2015-2019